SAN DIEGO, May 23, 2011 /PRNewswire/ — Aethlon
Medical, Inc. (OTC Bulletin Board:
AEMD), the pioneer in developing therapeutic filtration devices
to address infectious disease and cancer, announces that Chairman
and CEO James A. Joyce will present the Aethlon ADAPT™ system
in a presentation at the C21 BioVentures™ Life Sciences
Partnering Conference on Wednesday, May 26, 2011, at 3:00 p.m.
Pacific time at the Meritage Resort in Napa, Calif. The newly
introduced Aethlon ADAPT™ system is an adaptive dialysis-like
affinity platform technology that provides a less burdensome
medical device regulatory pathway for therapeutic antibodies and
other affinity drugs agents.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
“The C21 partnering conference is an ideal venue to introduce
our Aethlon ADPAPT™ system to senior drug industry executives
that are facing increasingly unpredictable regulatory challenges as
well as emerging competition from generics and biosimilars,” said
Mr. Joyce. “Our platform technology allows marketed drugs,
clinical-stage drugs, and agents that previously failed clinical
studies to be repurposed within a therapeutic filtration design
that results in an expedited and less costly medical device
pathway.”
The Aethlon ADAPT™ system allows for the selective removal
of disease-related particles from the entire circulatory system
without the loss of essential blood components. It eliminates
the need to infuse drug agents into the body as blood filtration
occurs ex vivo. As a result, new devices evolved from
this platform will not add drug toxicity or drug-drug interaction
risks if combined with other therapies. The Aethlon
ADAPT™ system also provides the potential to
‘/>”/>
